中西医三联药物方案治疗盆腔炎的效果较好

Better Effect of Chinese and Western Medicine Triple Drug Regimen on Pelvic Inflammatory Disease

为了探究中西医三联药物方案(康妇炎胶囊+左氧氟沙星+甲硝唑)治疗盆腔炎的效果,本研究将166例盆腔炎患者分为研究组(n=83)和对照组(n=83),研究组患者药物治疗方案为康妇炎胶囊+左氧氟沙星+甲硝唑,对照组患者药物治疗方案为左氧氟沙星+甲硝唑。考察两组治疗1个疗程(2个月)后的疗效、B超参数及SF-36生活质量量表评分。研究结果显示,治疗1个疗程后,对照组的治疗总有效率(80.72%)显著低于研究组(96.39%),差异具有统计学意义(p<0.05)。B超结果显示研究组的炎性包块和盆腔液渗出情况显著好于对照组,差异具有统计学意义(p<0.05)。研究组的生活质量评分(SF-36)也明显高于对照组(p<0.05),差异具有统计学意义。本研究表明中西医三联药物方案(康妇炎胶囊+左氧氟沙星+甲硝唑)可显著提高盆腔炎的临床疗效,并改善患者的生活质量。

To investigate the effect of Chinese and Western medicine triple drug regimen(Kangfuyan capsule +levofloxacin+metronidazole) in the treatment of pelvic inflammatory disease, 166 patients with pelvic inflammatory disease were divided into study group(n =83) and control group(n =83). The study group’s drug regimen was Kangfuyan capsule+levofloxacin+metronidazole, the control drug regimen was levofloxacin +metronidazole. The efficacy, B-parameter parameters and SF-36 quality of life scale scores of the two groups after one course of treatment(2 months) were examined. Studies have shown that after treatment for one course of treatment, the total treatment rate of the control group(80.72%) was significantly lower than the study group(96.39%), the difference was statistically significant(p<0.05). B-parameter parameters showed the inflammatory mass and pelvic fluid exudation of study group were significantly better than the control group, the difference was statistically significant(p<0.05). The quality of life score(SF-36) of the study group was significantly higher than that of the control group,the difference was statistically significant(p<0.05). It shows that the Chinese and Western medicine triple drug program(Kangfuyan capsule+levofloxacin+metronidazole) can significantly improve the clinical efficacy of pelvic inflammatory disease and improve the quality of life of patients.